Search results
Results From The WOW.Com Content Network
Currently, appearance of drug resistant viruses is an inevitable consequence of prolonged exposure of HIV-1 to antiretroviral therapy. Drug resistance is a serious clinical concern in treatment of viral infection, and it is a particularly difficult problem in treatment of HIV. [25] Resistance mutations are known for all approved NRTIs. [26]
In 2021, Viatris was ranked 5th by Fortune on its annual "Change the World" list for having "transformed the treatment of HIV around the world in the [previous] five years through the first low-cost antiretroviral drug for first-line treatment of HIV and a children's version in the form of fruit-flavored tablets that dissolve in liquid. [10]
AZT was usually dosed twice a day in combination with other antiretroviral therapies. This approach is referred to as Highly Active Antiretroviral Therapy and is used to prevent the likelihood of HIV resistance. [11] [12] As of 2019, the standard is a three-drug once-daily oral treatment that can include AZT. [13]
Resistance ranged from 3.9% to 8.6% and reached 19.6% among people who have received and transitioned to a dolutegravir-containing antiretroviral therapy (ART) regimen to combat high HIV viral loads.
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ...
Nelfinavir belongs to the class of drugs known as protease inhibitors (PIs) and like other PIs is almost always used in combination with other antiretroviral drugs. Nelfinavir is an orally bioavailable human immunodeficiency virus HIV-1 protease inhibitor (K i = 2 nM) and is widely prescribed in combination with HIV reverse transcriptase ...
PARIS (Reuters) -French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion in a bid to boost its rare ...
Ritonavir, sold under the brand name Norvir, is an antiretroviral medication used along with other medications to treat HIV/AIDS. [4] [5] [8] This combination treatment is known as highly active antiretroviral therapy (HAART). [8] Ritonavir is a protease inhibitor, though it now mainly serves to boost the potency of other protease inhibitors.